News Daily News Texting Tool Failed to Up Pill Adherence in ACS Patients: TEXTMEDS Caitlin E. Cox May 10, 2022
News Daily News Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV Michael O'Riordan May 09, 2022
News Daily News Good News and Bad for High-Intensity Statin Use in ASCVD Michael O'Riordan May 05, 2022
News Daily News Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol Michael O'Riordan March 15, 2022
News Daily News Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis Michael O'Riordan February 18, 2022
News Daily News Absence of CAC May be Protective Even in Patients With Very High Cholesterol Michael O'Riordan February 14, 2022
News Daily News Homozygous FH Diagnosis Often Comes Late, With Lackluster Care Michael O'Riordan February 10, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Daily News Another Study Links Stopping Statins to MACE in the Elderly Shelley Wood December 03, 2021
News Conference News AHA 2021 ApoB Gains Ground as Best Lipid Predictor of MI Risk Michael O'Riordan November 22, 2021
News Conference News AHA 2021 Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients Michael O'Riordan November 13, 2021
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Daily News Diabetes Progression in Statin-Treated Patients: VA Data Michael O'Riordan October 06, 2021
News Daily News Cumulative Burden of LDL Cholesterol Increases CHD Risk Michael O'Riordan September 23, 2021
News Daily News Heterozygous FH Diagnosed Late, Remains Undertreated Michael O'Riordan September 13, 2021
News Daily News Could an App Replace Statin Prescribing by Doctors? Michael O'Riordan September 08, 2021
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News ESC 2021 PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer Michael O'Riordan August 30, 2021